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Abstract The development of in vitro amplification systems
allows detecting femtomolar amounts of prion protein scrapie
(PrPSc) in human cerebrospinal fluid (CSF). We performed a
CSF study to determine the effects of prion disease type,
codon 129 genotype, PrPSc type, and other disease-related
factors on the real-time quaking-induced conversion (RT-
QuIC) response. We analyzed times to 10,000 relative fluo-
rescence units, areas under the curve and the signal maximum
of RT-QuIC response as seeding parameters of interest.
Interestingly, type of prion disease (sporadic vs. genetic) and
the PRNP mutation (E200K vs. V210I and FFI), codon 129
genotype, and PrPSc type affected RT-QuIC response. In ge-
netic forms, type of mutation showed the strongest effect on
the observed outcome variables. In sporadic CJD, MM1 pa-
tients displayed a higher RT-QuIC signal maximum compared
to MV1 and VV1. Age and gender were not associated with
RT-QuIC signal, but patients with a short disease course
showed a higher seeding efficiency of the RT-QuIC response.
This study demonstrated that PrPSc characteristics in the CSF
of human prion disease patients are associated with disease
subtypes and rate of decline as defined by disease duration.
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Abbreviations
AUC Areas under the curve
CSF Cerebrospinal fluid
FFI Fatal familial insomnia
PrPC Cellular prion protein
ROC Receiver operating Characteristic
RT-QuIC Real-time quaking-induced conversion




TSE Transmissible spongiform encephalopathy
PrPSc Scrapie prion protein
Introduction
Prion diseases are characterized by the accumulation of
abnormally misfolded prion protein (PrPSc) in the brain.
Spontaneous (sporadic), genetic, and transmitted forms of
prion diseases are known. In sporadic Creutzfeldt-Jakob dis-
ease (sCJD), molecular characteristics of PrPSc, and codon 129
genotype of the prion protein gene (PRNP) determine molec-
ular sCJD subtypes [1, 2] with distinct clinicopathological
phenotypes and transmission characteristics [3].
The two genetic CJDs (gCJD), examined in this study, are
defined by pathogenic PRNPmutations of E200K and V210I.
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Including the mutation D178N-129M (fatal familial insomnia;
FFI), these are the three most common PRNP mutations in
Europe [4-7].
Human prion diseases are unique with respect to their self-
propagating replication of the abnormally folded host-derived
prion protein (PrPC), which in its pathological conformation
(PrPSc) is prone to aggregation and seeding. Various in vitro
conversion assays, such as protein misfolding cyclic amplifi-
cation (PMCA), enhanced quaking-induced conversion
(eQuIC), or real-time QuIC (RT-QuIC) use this high aggrega-
tion and seeding activity to amplify miniscule amounts of
PrPSc to a detectable level.
While this worked well with brain material in various
settings, recent studies demonstrated the potential of RT-
QuIC to replicate PrPSc from human cerebrospinal fluid
(CSF) [8, 9]. Aggregated PrPSc detected by thioflavin-T (Th-
T) can be monitored in real-time, which is a key advantage of
RT-QuIC. The kinetic of the signal detection is used to eval-
uate the efficiency of the reaction. RT-QuIC can detect aggre-
gated PrPSc also in various artificial prion disease models such
as in the blood and the CSF of scrapie-infected hamsters [10,
11] and in scrapie-infected sheep [12].
In the present study, we applied RT-QuIC assay to human
CSF and analyzed the prion seeding efficiency in humanswith
different forms of genetic and sporadic prion diseases. Our
aim was to study the characteristics of the PrPSc seeding
response in human CSF samples and not to apply the RT-
QuIC as a diagnostic tool to diagnose gCJD or different sCJD
subtypes. We propose that the application of the RT-QuIC
method as a reliable diagnostic test for prion diseases can be
extended to show that PrPSc seeds from different prion dis-




The study included 110 prion disease patients consisting of 64
sporadic CJD, 39 genetic CJD (33 E200K-, 6 V210I mutation
carriers), and 7 FFI (D178N mutation) as well as 189 control
subjects. All sCJD (28 female, 36 male; aged 23–85 years;
mean age 64.5±1.5 years at notification; 21 MM, 25 MV, 18
VV), E200K (20 female, 13 male; aged 41–73 years; mean
age 60.3±1.5 years at notification, 14 MM and 19 MV),
V210I (3 female, 3 male; aged 52–67 years; mean age 59.1
±1.9 years at notification; 5 MM and 1 VV), and FFI patients
(1 female, 6male; aged 50–85 years;mean age 62.3±4.1 years
at notification; 4 MM, 2 MV, 1 VV) were diagnosed as
definite cases by neuropathological examinations [13–15].
Genetic evaluation for the E200K mutation was performed
on blood samples derived from putative E200K carriers and
the type of PrPSc was determined by autopsy.
Control group (86 female, 103 male; aged 16–87 years;
mean age 64.1±0.9 years at notification) composed patients
with either clinically or pathologically defined alternative
diagnosis. Our cohort consisted of Alzheimer’s disease pa-
tients (rapid progressive and classical forms, 35), alpha
synucleinopathies (Lewy body dementia, Parkinson’s disease,
32), psychiatric disorders (psychosis, bipolar disorder, schizo-
phrenia, 16), epilepsy (11), inflammatory and autoimmune
diseases (multiple sclerosis, meningitis, 34), and other non-
prion diseases (61).
The study was conducted according to the revised
Declaration of Helsinki and GoodClinical Practice guidelines.
Informed consent was given by all study participants or their
legal next of kin.
CSF Samples
All CSF samples were stored at −80 °C prior to analysis. The
analysis of the codon 129 genotype of PRNP was performed
after isolation of genomic DNA from blood samples accord-
ing to standard methods [16].
RT-QuIC Analysis
RT-QuIC analysis uses recPrP as a substrate to amplify small
amounts of a PrP seed in human CSF to a detectable limit
(comparable to a PCR for proteins). Converted and aggregated
PrP can be monitored in real time by a fluorescence dye
(thioflavin-T) analysis by a fluorescent reader.
Reaction buffer consisted of 162 mM phosphate buffer
(pH 6.9), 170 mM sodium chloride, 1 mM ethylenediamine-
tetraacetic acid (Sigma-Aldrich, Munich, Germany), 10 μM
thioflavin-T (Sigma-Aldrich, Munich, Germany), and
0.1 mg/ml recPrP. Eighty-five-microliter reaction buffer
was seeded with 15 μl freshly thawed, neat CSF to a final
volume of 100 μl. Reactions were prepared in a black 96-
well, optical-bottomed plate (VWR, Hannover, Germany).
Prepared plates were sealed (VWR, Hannover, Germany)
and incubated in a plate reader (FLUOStar OPTIMA, BMG
Labtech, Ortenberg, Germany) at 42 °C for 80 h with inter-
mittent shaking cycles, consisting of 1 min double orbital
shaking at the highest speed (600 rpm) followed by a 1-min
break. Fibril formation kinetics were determined by mea-
suring thioflavin-T fluorescent signal (450 nm excitation
and 480 nm emission) every 30 min.
Expression and Purification of Recombinant Hamster-Sheep
PrP
All RT-QuIC experiments were performed using the chimera
recPrP composed of the Syrian hamster residues 14 to 128
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followed by sheep residues 141 to 234 of the R154 Q171
polymorph [11]. The recPrP was prepared according to the
method described by Wilham et al. [17].
Briefly, DNA sequences coding for hamster (residues
90–231 and 23–231; accession K02234) and sheep (resi-
dues 25–234; accession AJ567988) recPrP residues were
amplified and ligated into the pET41 vector (EMD
Biosciences). Transformation of the plasmids occurs into
Escherichia coli Rosetta cells (EMD Biosciences).
RecPrP was expressed using the Overnight Express
Autoinduction system (EMD Biosciences). Isolated inclu-
sion bodies were denatured (6 M guanidine, 100 mM
sodium phosphate, 10 mM tris pH 8) and bound to Ni-
NTA Superflow resin (Qiagen, Hilden, Germany). Using
an AKTA Explorer system (GE Healthcare), the denatured
recPrP was refolded using a linear gradient to refolding
buffer (100 mM sodium phosphate, 10 mM tris pH 5.8).
After elution of recPrP applying a linear gradient (100
mM sodium phosphate, 10 mM Tris, 500 mM imidazole,
pH 5.8), the recPrP was dialyzed against 10 mM phos-
phate buffer pH 5.8 overnight and filtered with a 0.2-µm
syringe filter. The concentration of recPrP was determined
by measuring absorbance at 280 nm. The recPrP was
diluted to 0.5 mg/ml with 10 mM phosphate buffer pH
5.8 aliquoted and stored at −80 °C until analysis was
performed.
As a precaution to possible batch-to-batch variability of
recombinant PrP, batches were generally mixed in equal parts.
Functionality of the recPrP was verified by analyzing serial
dilutions of sCJD-infected brain homogenates in RT-QuIC
experiments according to the method described by Wilham
et al. [17].
Determination of the PrP Concentration
To determine the PrP concentration, we used a commer-
cial BetaPrion BSE-ELISA Test Kit (AJ Roboscreen,
Leipzig, Germany) and followed the manufacturer’s
instruction.
Analysis of CSF by ELISA for 14-3-3
Levels of 14-3-3 in CSF were determined by using the
CircuLex 14-3-3 Gamma ELISA Kit (BIOZOL Diagnostica
Vertrieb GmbH, Eching, Germany). We followed the manu-
facturer’s instructions. Briefly, CSF samples were used in a
dilution of 1:5 in dilution buffer. Level of 14-3-3 was detected
in arbitrary units (AU) per ml (1 AU is almost equal to 1 pg).
For capturing, samples were incubated for 1 h at room tem-
perature (25 °C). After washing, 14-3-3 gamma detection
antibody and later HRP conjugated anti-IgG antibody were
added and incubated for 1 h at room temperature each. The
colorimetric reaction was measured at 450 nm with a 1420
multilabel Counter Victor2 (Wallac) (PerkinElmer, MA,
USA).
Determination of Total Tau Level
CSF levels of total tau protein was measured using a commer-
cially available ELISA kit (INNOTEST® hTAU Ag,
Innogenetics). For the determination of tau level, we followed
the manufacturer’s instructions.
Briefly, before antibody incubations, each sample (75 μl)
was diluted 1:1 in sample diluent. The colorimetric reaction
was measured at 450 nm with a 1420 multilabel Counter
Victor2 (Wallac) (PerkinElmer, MA, USA). Each sample
was measured in duplicates. For analysis, we calculated the
median.
Statistical Analyses
For investigating differences between predefined groups,
three variables were defined as seeding parameters of
interest. First, areas under the curve (rel. AUC, concen-
tration over time) were calculated for each individual
sample and were transformed for convenience reasons
by dividing rel. AUC by the number of total measure-
ments. Rel. AUCs were checked for being normally dis-
tributed; means (and standard deviations (SD)) of rel.
AUCs were then calculated for the respective groups of
interest and were compared between groups using t-tests
and ANOVAs (+Tukey’s post-hoc tests) as appropriate. In
the second step, the maximum seeding activity was cal-
culated for each individual sample. Again, maximum
values were checked for being normally distributed and
then compared between group using means, t-test and
ANOVAs (+Tukey’s post-hoc tests). In the third step,
the time to 10,000 rfu was calculated for each individual
sample. Times to 10,000 rfu were compared using logrank
tests and Bonferroni-adjusted logrank tests (for pairwise
post-hoc testing). All analyses were conducted on an
exploratory basis only and were performed using SPSS
20.0 and R 2.15.
For graphical illustration, time series plots are pre-
sented at each step of the analysis displaying means (+
standard errors of the mean) of seeding activity for each
point in time (each measurement) in the respective
groups. Thus, these illustrations show aggregated data
for each time point; information about means of AUCs,
individual maximums, or times to 10,000 rfu cannot be
read out of these plots. Graphical “AUCs” (representing
the AUC of means at each time point) do not corre-
spond to calculated rel. AUCs (representing the mean of
individual AUCs).
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Results
RT-QuIC Assay Differentiates Between Genetic, Sporadic
and FFI-Seeded Samples
To investigate the effect of type of prion disease on RT-
QuIC response, we used CSF from sCJD, gCJD (E200K
and V210I), FFI, and non-prion disease control cases. The
optimal running time for RT-QuIC reaction was 80 h be-
cause no additional sCJD case became positive after this
time period. Therefore, a longer incubation period was not
required. From each individual sample, we calculated the
average from rel. AUC, times to 10,000 rfu (lag phase) and
the maximal intensity of Th-T fluorescence signal over a
time period of 80 h, using these parameters as indicators
for the seeding efficiency of the RT-QuIC reactions
(Fig. 1). The rel. AUC and the signal maximum were
higher while times to 10,000 rfu were shorter in gCJD than
in sCJD cases (Fig. 1a, b). The rel. AUC and the signal
maximum in sCJD were not significantly different from
those in FFI. The earliest signal increase to 10,000 rfu was
observed in gCJD cases (median 41 h), with sCJD cases
increasing significantly later (median 52.5 h). Patients with
FFI had the longest lag time before the first seeding could
be observed (Fig. 1a, b). The RT-QuIC response in controls
was lower than 10,000 rfu.
Fig. 1 Time course of prion
seeding efficiency detected by
RT-QuIC in the CSF of gCJD
(E200K and V210I), sCJD, FFI
patients, and non-prion disease
controls. a RT-QuIC responses of
all groups were measured in
relative fluorescence units (rfu)
over a period of 80 h. Displayed
are means+SEM (standard error
of the mean) at each point in time.
b The absolute values for rel.
AUC, maximal Th-T signal
(mean+standard deviation (SD)),
and time to 10,000 rfu (median+
IQR (interquartile range)) were
shown for each group, and the p-
values were calculated for each
comparative analysis. We
observed significant differences
between different types of prion
diseases. Genetic CJD (E200K
and V210I)-seeded reactions
showed the highest seeding
efficiency followed by sCJD and
FFI. For comparison between
groups, we used ANOVAs or t-
tests (rel. AUC) and logrank test
(time to 10,000 rfu) with Tukey’s
post-hoc tests and Bonferroni-
adjusted logrank test as
appropriate. All p-values<0.05
are considered as significant
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Impact of the Biological Characteristics of Various sCJD
Subtypes
To analyze the impact of PrPSc type or PRNP codon 129
polymorphism on the RT-QuIC response, we compared the
seeding efficiency from CSF samples derived from different
sCJD patients exhibiting PrPSc type 1 or 2 (independently
from codon 129 genotype) as well as different PRNP geno-
types (MM, MV, and VV). Neither the PrPSc type nor the
PRNP codon 129 genotype alone had a significant impact on
RT-QuIC response (supplemental Fig. 1).
We stratified the data by PrPSc type or codon 129 geno-
types and analyzed the rel. AUC, the lag phase and the signal
maximum of samples derived from the same type of PrPSc
with distinct PRNP codon 129 genotypes (Fig. 2a, b). Our
data revealed that the codon 129 genotype within PrPSc type 1
patients is associated with a shorter time to 10,000 rfu in MM
than in MV and VV patients (Fig. 2a, f). This effect was not
present in patients with PrPSc type 2 (Fig. 2b, f).
When stratifying the other way and analyzing subgroups of
patients exhibiting the same codon 129 genotype but distinct
PrPSc types (MM1 vs. MM2, MV1 vs. MV2 as well as VV1
Fig. 2 RT-QuIC analysis of the biological characteristics of various sCJD
subtypes. Reactions seeded with CSF derived from sCJD patients
exhibiting the same type of PrPSc with distinct PRNP codon 129 geno-
types (MM, MV, and VV) were performed for type 1 (a) and type 2 (b).
Displayed are means+SEM (standard error of the mean) at each point in
time. Comparison of the RT-QuIC responses revealed a higher maximum
in sCJD MM1-seeded samples compared to MV1 and VV1. (c–e) CSF-
seeded reactions from sCJD patients of the same codon 129 genotype
with different types of PrPSc were analyzed by RT-QuIC (mean+SEM). f
The absolute values for rel. AUC, maximal Th-T signal (mean+SD), and
time to 10,000 rfu (median+IQR) were shown for each group, and the p-
values were calculated for each comparative analysis. For comparison
between groups, we used ANOVAs or t-tests (rel. AUC) and logrank test
(time to 10,000 rfu) with Tukey’s post-hoc tests and Bonferroni-adjusted
logrank test as appropriate. All p-values<0.05 are significant
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vs. VV2) (Fig. 2c–e), no significant differences could be
observed (Fig. 2f).
Impact of Codon 129 Genotype in gCJD
When restricting analyses to E200K patients, RT-QuIC re-
sponse was significantly shorter in MM patients (median time
to 10,000 rfu 27 h compared to 44 h in MV patients,
p<0.001), whereas there was some evidence for a difference
of rel. AUC (Fig. 3a, d).
After stratifying by codon 129 genotype and restricting the
analysis to MM carriers, type of PRNP mutation had a signif-
icant effect on the seeding efficiency in both gCJD groups
(E200K and V210I) when compared to sCJD (Fig. 3b, d).
Patients with E200K mutation revealed the highest seeding
efficiency (median 27 h to reach 10,000 rfu), followed by
V210I (median 38.5 h), sCJD (median 52.5 h) (Fig. 3b, d).
This was consistent in 19 gCJD cases with MV genotype,
which were compared to 25 sCJD cases from the same codon
129 genotype (Fig. 3c).
Influence of Age at Onset, Gender, Disease Duration,
and Time of Lumbar Puncture
Different disease-related characteristics and hence potential
confounders were assessed for a possible association with
RT-QuIC response. Age groups (younger than 60, between
60 and 70, and older than 70 years), different genders or
different PrPSc strains, defined by Bishop et al. [3] showed
no effect on RT-QuIC response (supplemental Fig. 1). To
analyze the effect of the time from disease onset, we grouped
patients in early, middle, or late disease stage.
According to Fig. 4a, sCJD (early) patients seem to have a
shorter lag phase and the Th-T intensity may increase earlier
compared to the other two disease stages. However, these
differences are not significant because of a low number and a
Fig. 3 RT-QuIC analysis of different PRNP codon 129 genotypes in
gCJD patients and different prion diseases of the same codon 129 geno-
type. a Reactions seeded with CSF derived from gCJD (E200K) patients
with codon 129 genotypes MM and MV revealed a higher RT-QuIC
response inMM than in MV cases. Displayed are means+SEM (standard
error of the mean) at each point in time. b–c Comparison of gCJD- and
sCJD-seeded reactions exhibiting either the codon 129 genotype MM or
MV revealed that the type of prion disease has a significant effect on the
RT-QuIC reaction (mean+SEM). d The absolute values for rel. AUC,
maximal Th-T signal (mean+SD), and time to 10,000 rfu (median+IQR)
were shown for each group, and the p-values were calculated for each
comparative analysis. For comparison between groups, we used
ANOVAs or t-tests (rel. AUC) and logrank test (time to 10,000 rfu) with
Tukey’s post-hoc tests and Bonferroni-adjusted logrank test as appropri-
ate. All p-values<0.05 are significant
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high variation of the RT-QuIC seeding response in this
group. Unfortunately, we cannot resolve this issue because
sCJD samples with an early disease state are sparely avail-
able. When analyzing the effect of disease duration, a
higher seeding efficiency, indicated by a higher rel. AUC
and shorter lag phase, was observed in patients with short,
thus more aggressive disease followed by medium and
long disease duration (Fig. 4b, c). Due to low sample
numbers, stratification of the disease duration dataset by
CJD subtype was not performed.
End-Point Dilution Analysis of sCJD and gCJD Samples
Since gCJD exhibited a higher seeding efficiency than sCJD
samples, we aimed to estimate the amount of PrPSc seed in
sCJD and gCJD (E200K) CSF-seeded RT-QuIC reactions and
performed an end-point analysis each with three randomly
chosen samples. We used six serial dilutions from 1:4 to
1:24 and calculated the percentage of the number of positive
replicates within the first 80 h for each dilution. In both
groups, we observed a clear correlation between the amount
of CSF seed and the number of positive replicates in the RT-
QuIC assay (Fig. 5a). Sporadic CJD- and gCJD (E200K)-
seeded reactions showed no significant difference in their
seeding activities, which suggests an equal amount of PrPSc
seeds in CSF in both groups (Fig. 5a).
PrP Concentration is not Associated with the Seeding
Efficiency
Concentration of whole PrP (which is mainly due to PrPC and
extremely low concentrations of PrPSc) was determined by
ELISA in the CSF of 26 randomly selected sCJD patients and
tested for an association with seeding efficiency in the RT-
QuIC assay. No association between whole PrP concentration
and lag phase was observed, which indicates that the amount
of whole PrP had no influence on the RT-QuIC response
(Fig. 5b).
Dependence of RT-QuIC Seeding Response from the Degree
of Neuronal Damage
To investigate whether the PrP seeding efficiency depends on
neuronal damage, we analyzed sCJD samples (n=30) parallel
Fig. 4 Effect of time from disease onset and disease duration. aRT-QuIC
responses were grouped as to the time when the lumbar puncture was
performed, i.e., in early, middle, or late disease stage, showing that
disease stage had no significant effect on the seeding efficiency.
Displayed are means+SEM (standard error of the mean) at each point
in time. b RT-QuIC responses were grouped according to three different
disease durations (<3, 4–6, and >6 months). A short duration was
associated with a higher seeding efficiency. c The absolute values for
rel. AUC, maximal Th-T signal (mean+SD), and time to 10,000 rfu
(median+IQR) were shown for each group, and the p-values were calcu-
lated for each comparative analysis. For comparison between groups, we
used ANOVAs or t-tests (rel. AUC) and logrank test (time to 10,000 rfu)
with Tukey’s post-hoc tests and Bonferroni-adjusted logrank test as
appropriate. All p-values<0.05 are significant
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by 14-3-3-, tau ELISA, and RT-QuIC. Afterwards, we corre-
lated the RT-QuIC seeding signal response with the level of
total tau and 14-3-3 protein, which are known markers of
neuronal damage. However, the correlation of 14-3-3 level
with RT-QuIC (real-time quaking-induced conversion) results
was not significant (Spearman’s rho=0.06, p=0.74 for time to
10,000 rfu, rho=0.18, p=0.19 for maximum seeding activity).
The same could be observed, when we compared the tau level
and the RT-QuIC seeding response (tau and time to 10,000:
Spearman’s rho=0.0486 (p=0.785), tau and maximum:
Spearman’s rho=−0.0848 (p=0.624).
Discussion
We studied the influence of the phenotype of human prion
diseases on prion seeding efficiency in the CSF using the
recently established RT-QuIC assay.
According to the data presented here, CSF from gCJD has a
higher prion seeding efficiency in the RT-QuIC than CSF from
sCJD and FFI patients. Only sparse information on this topic
is available in the literature. Data reported by Sano et al. did
not mention the difference between genetic and sporadic
cases. However, looking at the individual data, differences
similar to those in our study, can be seen [18].
There are several ways to explain the more rapid kinetics of
the aggregation process in genetic, sporadic CJD and between
different mutations in PRNP, such as, e.g., differences in the
concentration, structure, and stability of the PrP molecule or
infectivity of PrPSc (aggregates). So far, our knowledge of
PrPSc characteristics in gCJD originates from studies using
brain material. Accordingly, in E200K or V210I mutation
carriers, the disease is caused by an altered structure of PrPC
[19] and the metabolism of PrP is different during life [20].
These conformational changes might engender its conversion
into PrPSc by affecting the interactions with other cellular
partners or the fibrillation process of PrP [21]. Also, charac-
teristic indicators might be an increased generation of truncat-
ed fragments [20] and changed glycoform ratios of PrPSc in
the brain [22].
For FFI, where the N-terminal part of PrPC (23–90) plays
an important role for the conversion of protein [23], several
peculiar biological characteristics have been observed: low
amounts of PrPSc in the brain of affected individuals, a clear
effect of the codon 129 genotype on disease onset and disease
phenotype, and low transmission rates in animal experiments
with very long incubation times [24, 25], when compared to
genetic forms of CJD (E200K) and sporadic prion diseases [4,
26, 27]. While this does not explain the early age at onset in
FFI, our observation on low and slow seeding activities of FFI
patients in RT-QuIC assays fits well with the known biological
factors of this disease form. The molecular diversity of spo-
radic forms of CJD has been recognized and studied for many
years and was explained at least in part by the peculiar PrPSc
Fig. 5 RT-QuIC end-point
dilution of sCJD and gCJD CSF
seeded RT-QuIC reactions. a CSF
from sCJD (n=3) and gCJD
E200K (n=3) was serially diluted
in control CSF and used as seeds
for RT-QuIC assay. We calculated
percentage of positive replicates
(n=4). The number of positive
replicates correlated with the
dilution factor showing no
significant differences between
sCJD and gCJD patients. b PrPC
concentration in CSF was
correlated to the prion seeding
activity in sCJD patients. No
correlation between amount of
PrPC and RT-QuIC response
could be observed
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characteristics and PRNP codon 129 genotype [1, 28].
Therefore, we focused on the effect of sCJD genotype and
PrPSc types on the prion seeding efficiency in the RT-QuIC
assay. Patients with sCJD can be categorized according the
PRNP codon 129 genotype and the biochemical characteris-
tics of PrPSc into six molecular subtypes [29]. The subtypes
MM1 and MV1 represent the classic sCJD phenotype and
subtypes, such asMM2 or VV1, are less typical. Transmission
experiments demonstrated characteristic incubation times and
neuropathological lesion profiles, when brain material from
patients with distinct molecular subtypes was inoculated in a
panel of mice expressing different forms of human PRNP
(MM, MV, and VV) [3]. Following these experiments and
based on the transmission characteristics and PK resistances
of these subtypes [30], the existence of four potential human
strains was suggested: MM1 and MV1 as the classic pheno-
type of sCJD, MV2 and VV2, and VV1 and MM2.
Recent work using RT-QuIC assay on brain tissue demon-
strated distinct RT-QuIC responses in single sCJD subtypes.
In particular, atypical CJD (MM2 or VV1) or variant CJD
samples showed a lower seeding efficiency compared to sCJD
MM1 and MV1, indicating a delayed and slower conversion
process in these samples [31].
To study the effect of the codon 129 genotype or PrPSc type in
CSF separately, we performed a comparative analysis of three
sCJD codon 129 genotypes (MM, MV, and VV) and two PrPSc
types (1 and 2). In doing so, we tested both factors separately and
examined the impact of codon 129 genotype in patient groups of
the same PrPSc type. In addition, we compared sCJD patient
groups with the same codon 129 genotype, but different PrPSc
types, and found an effect of the PRNP codon 129 genotype on
RT-QuIC response.Methionine homozygosity at codon 129 was
associated with a higher signal maximum of RT-QuIC response,
which could be shown in sCJD MM1 patients as opposed to
sCJD MV1 or VV1 patients. However, we could not observe
any difference when comparing the RT-QuIC responses by
grouping our study participants according to the suggested four
PrPSc strains [3] as defined by those experiments.
In E200K cases, the RT-QuIC assay showed a shorter lag
phase and higher rel. AUC in MM than in MV genotypes,
suggesting a higher seeding efficiency in homozygous patients.
There is a remarkable parallel to the observation that in E200K
patients, codon 129 genotype has a major influence on the risk
and disease characteristics, such as earlier age at onset and
shorter disease duration (3.7 +/−2.0 months compared to 7.84
+/−7.3 months) [32].
The question remains as to which factors may influence the
kinetics of RT-QuIC response in addition to PrPSc type, type
of PRNP mutation, and codon 129 genotype.
Interestingly, in sCJD patients, we found that the disease
duration had an impact on the seeding efficiency of PrP, e.g.,
patients with short disease courses showed a higher seeding
efficiency in the RT-QuIC response.
Since the whole PrP concentration has no influence on the
seeding efficiency, other factors might also be important, such
as the amount of PrPSc seed in the CSF. However, performing
a serial dilution of gCJD and sCJDCSF samples, we could not
find any differences between both groups. We suggest that
conformational or structural differences in the PrPSc seed,
caused by the mutation in gCJD, may be the decisive factor
responsible for the increased RT-QuIC response in gCJD,
rather than the amount of PrPSc seeds.
These findings together raise questions about the structure
and characteristics of PrP in human CSF, which might be
different from those in the brain of affected individuals. In
conclusion, the data obtained confirms that the RT-QuIC assay
allows us to study the characteristics of PrPSc seeding effi-
ciency in human CSF. It clearly shows that PrPSc characteris-
tics in the CSF of humans with a prion disease are distinct and
modulated by the type of prion disease, codon 129 genotype
and rate of decline as defined by disease duration. For the first
time, a method can be applied to study these effects in humans
affected by the disease during the symptomatic phase.
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